|
Wednesday, April 26, 2023, San Antonio, Texas, 6:00 PM – 8:00 PM Central Time (7:00 PM – 9:00 PM Eastern Time)
What I Tell My Patients: Expert Insights into Patient Education on New Treatments and Clinical Trial ParticipationFifteenth Annual RTP Symposium Series Held During the Annual ONS CongressBreast Cancer
Location
Grand Hyatt San Antonio River Walk 600 E Market Street San Antonio, TX 78205 Hotel Phone: (210) 224-1234 Program Schedule — Central Time 5:30 PM – 6:00 PM — Registration 6:00 PM – 8:00 PM — Dinner Meeting Meeting Room Texas Ballroom (Salons A-C) – Fourth Floor This event will also be webcast live. Please see Registration tab for details. Faculty
Jamie Carroll, APRN, MSN, CNP Mayo Clinic Rochester, Minnesota Virginia Kaklamani, MD, DSc Professor of Medicine Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment AB Alexander Distinguished Chair in Oncology Leader, Breast Oncology Program UT Health San Antonio MD Anderson Cancer Center San Antonio, Texas Joyce O’Shaughnessy, MD Celebrating Women Chair in Breast Cancer Research Baylor University Medical Center Director, Breast Cancer Research Program Texas Oncology US Oncology Dallas, Texas Ronald Stein, JD, MSN, NP-C, AOCNP Clinical Instructor of Medicine USC Norris Comprehensive Cancer Center Los Angeles, California Moderator Neil Love, MD Research To Practice Miami, Florida Meeting space has been assigned to provide a satellite symposium supported by AstraZeneca Pharmaceuticals LP, Exact Sciences Corporation, Lilly, Merck, Puma Biotechnology Inc, Seagen Inc, and TerSera Therapeutics LLC during the Oncology Nursing Society’s (ONS) 48th Annual Congress, April 26–30, 2023 in San Antonio, Texas. The Oncology Nursing Society's assignment of meeting space does not imply product endorsement.
Program Schedule — Central Time
5:30 PM – 6:00 PM — Registration 6:00 PM – 8:00 PM — Educational Dinner Meeting What I Tell My Patients About ... Neoadjuvant and Adjuvant Therapy for Localized HER2-Positive Breast Cancer
Available Therapies for HER2-Positive Metastatic Breast Cancer (mBC)
New Treatment Options for HER2-Low mBC
The Incidence and Management of Toxicities with T-DXd for Breast Cancer
The Tolerability of HER2-Targeted Tyrosine Kinase Inhibitors (TKIs) Used in the Treatment of Breast Cancer
The Utility of Genomic Assays in Treatment Decision-Making for ER-Positive, HER2-Negative Localized Breast Cancer
Adjuvant Endocrine Therapy for ER-Positive Localized Breast Cancer
The Role of CDK4/6 Inhibitors in Therapy for Localized ER-Positive Breast Cancer
Currently Available Therapies for ER-Positive mBC
The Role of PARP Inhibitors in the Management of Breast Cancer
The Tolerability of PARP Inhibitors for Patients with Breast Cancer
The Role of Immune Checkpoint Inhibitors in the Treatment of Triple-Negative Breast Cancer (TNBC)
The Tolerability of Immune Checkpoint Inhibitors for Patients with TNBC
Promising Investigational Strategies in Breast Cancer Management
Target Audience
Accreditation Statement Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Ms Carroll — Advisory Committee: Lilly, Pfizer Inc, Sanofi, Sermonix Pharmaceuticals. Dr Kaklamani — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, Puma Biotechnology Inc, TerSera Therapeutics LLC; Contracted Research: Eisai Inc; Data and Safety Monitoring Board/Committee: Bristol-Myers Squibb Company; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Exact Sciences Corporation, Genentech, a member of the Roche Group, Gilead Sciences Inc, Novartis, Pfizer Inc, Seagen Inc. Dr O’Shaughnessy — Advisory Committee and Consulting Agreements: AbbVie Inc, Agendia Inc, Amgen Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Carrick Therapeutics, Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, Fishawack Health, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genzyme Corporation, Gilead Sciences Inc, GSK, Incyte Corporation, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Ontada, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Pierre Fabre, Puma Biotechnology Inc, Roche Laboratories Inc, Samsung Bioepis, Sanofi, Seagen Inc, Stemline Therapeutics Inc, Synthon, Theralink, Veru; Nonrelevant Financial Relationship: prIME Oncology. Mr Stein — Advisory Committee: AstraZeneca Pharmaceuticals LP.MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc. RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose. SupportersThis activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Exact Sciences Corporation, Lilly, Merck, Puma Biotechnology Inc, Seagen Inc, and TerSera Therapeutics LLC. Grand Hyatt San Antonio River Walk Meeting Room: The Grand Hyatt San Antonio is the headquarters hotel for the 2023 ONS Congress and is conveniently connected to the Henry B González Convention Center.
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer.
IN-PERSON registration
Thank you for your interest in our NCPD program taking place in San Antonio, Texas. At this time online preregistration for in-person is closed for this event. LIMITED SEATS ARE STILL AVAILABLE FOR THIS SESSION. Our onsite registration desk will be open at 5:30 PM Central Time on Wednesday, April 26th. If you are interested in attending, please visit our registration desk located outside the Texas Ballroom (Salons A-C) – Fourth Floor of the Grand Hyatt San Antonio River Walk hotel which is connected to the Henry B Gonzalez Convention Center.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com. Please note, onsite registration does not guarantee seating and participation in meal service and will be based on availability. LIVE WEBCAST registration open to all professionals
Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions. Registration for Webcast »Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings. Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.
|